




References

REFERENCES

1. *Abdullah, N.; Voronovitch, L.; Taylor, S. and Lippmann, S. (2003):*
Olanzapine and haloperidol: potential for neutropenia?
Psychosomatics, 44(1): 83-4.
2. *Acri, A. A. and Henreting, F. M. (1998):*
Effects of risperidone in overdose. *Am. J. Emerg. Med.*,
16(5): 498-501.
3. *Adams, B. W. and Moghaddam, B. (2001):*
Effect of clozapine, haloperidol, or M100907 on
phencyclidine-activated glutamate efflux in the prefrontal
cortex. *Biol. Psychiatry*, 50(10):750-7.
4. *Aghajanian, G. K. and Marek, G. J. (1999):*
Serotonin and hallucinogens. *Neuropsychopharmacology*,
21:12S-23S.
5. *Akbarian, S.; Kim, J. J.; Potkin, S. G.; Hagman, J. O.; Tafazzoli, A.;
Bunny, r., W. E. and Jones, E. G. (1995):*
Gene expression for glutamic acid decarboxylase is reduced
without loss of neurons of prefrontal cortex of
schizophrenics. *Arch. Gen. Pschiatry*, 52, 258-266.
6. *Alao, A. O.; Malhorta, K. and Dewan, M. J. (2002):*
Comparing the side effect profile of the atypical
antipsychotics. *West. Afr. J. Med.*, 21(4): 313-5.
7. *Allison, D. B.; Mentore, J. L.; Heo, M.; Chandler, L. P.; Cappelleri,
J. C.; Infante, M. C. and Weiden, P.J. (1999):*
Antipsychotic-induced weight gain: a comprehensive
research synthesis. *Am. J. Psychiatry*, 156:1686-1696.
8. *Andreasen, N. D. and Olsen, S. A. (1992):*
Negative versus positive schizophrenia: definition and
validation. *Arch. Gen. Psychiatry*, 39: 789-794.

9. **Arvanov, V. L. and Wang, R. Y. (1999):**
Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. *J. Pharmacol. Exp. Ther.*, 289: 1000-1006.
10. **Baldessarini, R. J. (1985):**
Chemotherapy in psychiatry: Principles and Practice, 2nd ed. Harvard University Press, Cambridge, MA.
11. **Ballmaier, M.; Zoli, M.; Mazzoncini, R.; Gennarelli, M. and Spano, F. (2001):**
Combined alpha 2-adrenergic / D2 dopamine receptor blockade fails to produce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. *Psychopharmacology- (Berl.)*, 159(1): 105-10.
12. **Beauchemin, M. A.; Millaud, F. and Nguyen, K. A. (2002):**
A case of neuroleptic malignant syndrome with clozapine and risperidone. *Can. J. Psychiatry*, 47(9): 886.
13. **Berecz, R.; Lerena, A.; de La Rubia, A.; Gomez, J.; Kellerman, M.; Dorado, P. and Degrell, I. (2002):**
Relationship between risperidone and 9-hydroxy-risperidone concentrations and CYP 2D6 enzyme activity in psychiatric patients. *Pharmacopsychiatry*, 35(6): 231-4.
14. **Bharti, N. and Shende, D. (2003):**
Comparison of anti-emetic effects of ondansetron and low-dose droperidol in pediatric strabismus surgery. *J. Pediatr. Ophthalmol. Strabismus*, 40(1): 23-6.
15. **Biswas, A. K.; Zabrocki, L. A.; Mayes, K. L. and Morris-Kukoski, C. L. (2003):**
Cardiotoxicity associated with international ziprasidone and bupropion overdose. *J. Toxicol. Clin. Toxicol.*, 41(1):79-82.
16. **Bizouard, P.; Vandel, S. and Kantelip, J. P. (2001):**
Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report. *Therapie.*, 56(4): 443-5.

17. **Blaho, K. (2000):**
Monitoring patients at risk of drug-induced opacities. *J. Ophthalmol. Technol.*, 19(6): 302-3.
18. **Blanchet, P. J. (2003):**
Antipsychotic drug-induced movement disorders. *Can. J. Neurol. Sci.*, 30(1): S101-7.
19. **Bobes, J.; Rejas, J.; Garcia-Garcia, M.; Rico-Villademros, F. and Garci-Portilla, M. P. (2003):**
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: results of EIRE study. *Schizophr. Res.*, 62(1-2): 77-88.
20. **Borison, R. (1991):**
Risperidone versus haloperidol versus placebo in treatment of schizophrenia. Clinical Research Report RIS-USA-9001, August.
21. **Borrel, J.; Vela, J. M.; Arevalo-Martin, A.; Molina-Holgado, E. and Guaza, C. (2002):**
Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia, *Neuropsychopharmacology*, 26(2):204-15.
22. **Bradford, D. W.; Chakos, M. H.; Sheitman, B. B. and Lieberman, J. A. (1998):**
Atypical antipsychotic drugs in treatment of refractory schizophrenia. *Psychiat. Ann.*, 28: 618.
23. **Bradley, P. D.; Engel, G.; Feniuk, W.; Fozard, J. R.; Humphery, P. A.; Middlemiss, D. N.; Mylecharane, E. J.; Richardson, B. P. and Saxena, P. R. (1986):**
Proposals for classification and nomenclature of functional receptors for 5-hydroxytryptamine. *Neuropsychopharmacology*, 25: 563-576.
24. **Brevik, A. and Farver, D. (2003):**
Atypical antipsychotic-induced mild hypothermia. *S. D. J. Med.*, 56(2): 67-70.

25. **Brown, J. S. Jr. (2001):**
A novel mechanism to explain protein abnormalities in schizophrenia based on the flavivirus resistance gene. *Mol. Psychiatry*, 6(6): 701-11.
26. **Bums, M. J. (2001):**
The pharmacology and toxicology of atypical antipsychotic agents. *J. Toxicol. Clin. Toxicol.*, 39(1): 1-14.
27. **Bystritsky, A.; Liberman, R.P.; Hwang, S.; Wallace, C.J.; Vapink, T.; Maindment, K. and Saxena, S. (2001):**
Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. *Depress. Anxiety*, 14(4):214-8.
28. **Caccia, S. (2002):**
New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. *Curr. Opin. Invest. Drugs*, 3(70): 1073-80.
29. **Carmen, J.; Peuskens, J. and Vageneugden, A. (1995):**
Risperidone in the treatment of negative and positive symptoms of schizophrenia: a meta-analysis. *International J. Psychopharmacol.*, 10: 207-312.
30. **Carroll, D.H.; Shyam, R. and Scahill, L. (2002):**
Cardiac conduction and antipsychotic medication. *J. Child. Adolesc. Psychiatr. Nurs.*, 15(4): 170-7.
31. **Carter, D.; Champney, M.; Hwang, B. and Eglen, R. M. (1995):**
Characterization of post-junctional 5-hydroxytryptamine (5-HT) receptors of guinea pig ileum. *Eur. J. Pharmacol.*, 280: 243-250.
32. **Castagnoli, N. Jr.; Castagnoli, K. P.; Van der Schyf, C. J.; Usuki, E.; Igarashi, K.; Steyn, S. J. and Riker, R. R. (1999):**
Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. *Pol. J. Pharmacol.*, 51:31-38.

33. Chaudhry, I. B.; Soni, S. D.; Hellwell, J. S. E. and Deakin, J. F. W. (2002):
Effects of the 5-HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. *Schizophr. Res.*, 53(1-2): 17-24.
34. Chouinard, G.; Jones, B. and Remington, G. (1993):
A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia. *J. Clin. Psychopharmacol.*, 13: 25-40.
35. Christopher, S. T. and Shôn, L. (1998):
Which atypical antipsychotic. *Br. J. Psychiatry*, 172: 106-109.
36. Civelli, O. (1995):
Molecular biology of the dopamine receptor subtypes. In, *Psychopharmacology: The Fourth Generation of Progress*. (Bloom, F. E. and Kupfer, D. J., eds.) Raven Press, New York, pp. 155-162.
37. Claus, A.; Bollen, J.; DeCuyper, H.; Eneman, M.; Malfroid, M.; Peuskens, J. and Heylen, S. (2000):
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. *Am. J. Med.*, 100: 5-12.
38. Conlon, L.; Fahy, T.J.; Otoole, R.; Gilligan, J. and Prescott, P. (2002):
Risperidone in chronic schizophrenia: a detailed audit, open switch study, and 2-year follow-up of patients on depot medication. *Eur. J. Psychiatry*, 17(8): 459-65.
39. Costa, E.; Davis, J.; Pesold, C.; Tueting, P. and Guidotti, A. (2002):
The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. *Curr. Opin. Pharmacol.*, 2(1):56-62.
40. Creese, I.; Burt, D. and Snyder, S. H. (1978):
Biochemical actions of neuroleptic drugs. In, *the Handbook of Psychopharmacology*. vol. 10. New York, pp. 39-87.

41. *Creutzfeldt, W. and Stöckman, F. (1987):*
Carcinoids and carcinoid syndrome. *Am. J. Med.*, (5B): 4-16.
42. *Daniel, W. A. (2003):*
Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 27(1): 65-73.
43. *Dean, B. (2003):*
The cortical serotonin 2A receptor and the pathology of schizophrenia: a likely accomplice. *J. Neurochem.*, 85(1): 1-13
44. *Dean, B.; Pavey, G.; McLeod, M.; Oakes, K.; Keks, N. and Copolov, D. (2001):*
A change in the density of [(3) H] flumazenil, but not [(3) H] muscimol binding, in Brodmann's area 9 from subjects with bipolar disorder. *J. Affect. Disord.*, 66(2-3): 147-58.
45. *DeBattista, C. and Schatzberg, A. F. (1999):*
Universal psychotropic dosing and monitoring guidelines. *The Economics of Neuroscience (TEN)*, 1:75-84.
46. *De Bruin, M. L.; Hoes, A. W. and Leufkens, H. G. (2003):*
QT interval prolonging drugs and hospitalization for cardiac arrhythmias. *Am. J. Cardiology*, 91 (1): 59-62.
47. *Demoen, P. J. A. W. (1961):*
Haloperidol. *J. Pharm. Sci.*, 50: 350.
48. *de-Paulis, T. (2001):*
M-100907 (Aventis). *Curr. Opin. Investig. Drugs*. 2(1): 123-32.
49. *DeVane, C. L. and Nemeroff, C.B. (2000):*
Psychotropic drugs interactions. *The Economics of Neuroscience (TEN)*, 2:55-75.

50. *Dethi, S. and Bhargava, S. C. (2003):*
Clozapine-induced rabbit syndrome. *J. Clin. Psychiatr.*,
64(2): 219.
51. *Dickson, R. A. and Glazer, W. M. (1999):*
Neuroleptic-induced hyperprolactinemia. *Schizophr. Res.*,
35(Suppl.): S75-S86.
52. *Donatini, B.; Le Blaye, I. and Krupp, P. (1992):*
Transient cardiac pacing is insufficiently used to treat
arrhythmia associated with Thioridazine. *Cardiology*, 81:
340-1.
53. *Duggan, L. and Brylewski, J. (2001):*
Antipsychotic medication for those with both schizophrenia
and learning disability. *Cochrane Database Sys. Rev.* 2:
CD000030.
54. *Duncan, G. E.; Leipzig, J. N.; Mailman, R. B. and Lieberman, J. A. (1998b):*
Differential effects of risperidone and haloperidol on
ketamine-induced metabolic activation. *Brain Res.*, 812: 65-
75.
55. *Eastwood, S. L.; Burnt, P. W.; Gittins, R.; Baker, K. and Harrison, P.J. (2001):*
Expression of serotonin 5-HT_{2A} receptors in the human
cerebellum and alterations in schizophrenia. *Synapse.*, 42
(2): 104-14.
56. *Egan, M. F.; Hyde, T. M.; Bonomo, J. B.; Mattay, V.S.; Bigelow, L. B.; Goldberg, T. E. and Weinberger, D. R. (2001):*
Relative risk of neurological signs in siblings of patients
with schizophrenia. *Am. J. Psychiatry*, 158(11): 1827-34.
57. *Eklund, M. and Hansson, L. (2001):*
Determinants of satisfaction with community-based
psychiatric services: a cross-sectional study among
schizophrenia outpatients. *Nord. J. Psychiatry*, 55(6):413-8.

58. Ellis, K. A. and Nathan, P. J. (2001):
The pharmacology of human working memory. *Int. J. Neuropsychopharmacol.*, 4(3): 299-313.
59. Elman, I.; Goldstein, D. S.; Green, A. I.; Eisenhofer, G.; Folio, C. J.; Holmes, P. D. and Breier, A. (2002):
Effects of risperidone on the peripheral noradrenergic system in patients with schizophrenia: a comparison with clozapine and placebo. *Neuropsychopharmacology*, 27(2): 293-300.
60. Emsley, R. and Oosthuizen, P. (2003):
The new and evolving pharmacotherapy of schizophrenia. *Psychiatr. Clin. North Am.*, 26(1): 141-63.
61. Ereshefsky, L. (1996):
Pharmacokinetics and drug interactions: update for new antipsychotics. *J. Clin. Psychiatry*, 57(11):12-25.
62. Farber, N. B.; Kim, S. H.; Dikranian, K.; Jiang, X. P. and Heinkel, C. (2002):
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. *Mol. Psychiatry*, 7(1): 32-43.
63. Findling, R. L.; Schulz, S. C.; Reed, M. D. and Blumer, J. L. (1998):
The antipsychotics. A pediatric perspective. *Pediatr. Clin. North Am.*, 45:1205-1232.
64. Foote, S. L. (1997):
The locus coeruleus: the chemical neuroanatomy of the nucleus, its efferent projections, and its target receptors. In, *Handbook of Chemical Neuroanatomy*. Vol. 13 (Bloom, F. E.; Bjöeklund, A.; Hökfelt, T., eds.) Elsevier, Amsterdam, pp. 187-215.
65. Fornaro, P.; Calabria, G.; Corallo, G. and Picotti, G. B. (2002):
Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotic drugs: a dopamine hypothesis. *Doc. Ophthalmol.*, 105(1): 41-9.

66. *Frank, S. D. (1998):*
Effects of continuous D-amphetamine and phencyclidine on social, behavior, stereotyped behavior, and locomotor activity in rats. *Neuropsychopharmacology*, 21:74-81.

67. *Freedman, R.; Leonard S.; Olincy, A.; Kaufman, C.A.; Malaspina, D.; Cloninger, C. R.; Svrakic, D.; Faraone, S. V. and Tsuang, M. T.(2001):*
Evidence for the multigenic inheritance of schizophrenia. *Am. J. Med. Genet.*, 105(8): 794-800.

68. *Friedman, J. H. (2003):*
Atypical antipsychotics mechanisms of actions. *Can. J. Psychiatry*, 48(1): 62.

69. *Friedman, J. I.; Adler, D. N. and Davis, K. L. (1999):*
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. *Biol. Psychiatry*, 46(9): 1243-52.

70. *Fritzsche, M. and Schmidli, J. (2002):*
Seasonal fluctuation in schizophrenia. *Am. J. Psychiatry*, 159(3): 499-500.

71. *Furchgott, R. F. and Bhadrakom, S. (1953):*
Reaction of strips of Rabbit aorta to epinephrine Isopropyl artenol, sodium Nitrate, and other drugs. *J. Pharmacol. Exp. Ther.*, 106: 129-143.

72. *Galetin, A.; Clarke, E. E. and Houston, J. B. (2002):*
Quinidine and haloperidol as modifiers of CYP3 A4 activity. Multisite kinetic model approach. *Drug Metab. Dispos.*, 30(12): 1512-22.

73. *Galey, D. and Jaffard, R. (1992):*
Post-training medial septal stimulation improves spatial information processing in BALBIC mice. *Neurosci., Lett.*, 143: 87-90.

74. Gary, E. D.; Seiya, M.; Jeremy, N. and Jeffrey, A. L. (2000): Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. *J. Pharmacol. Exp. Ther.*, 293(1): 8-14.
75. George, T. P.; Vessicchio, J. C.; Termine, A.; Shady, D. M.; Head, C. A.; Pepper, W. T.; Kosten, T. R. and Wexler, B. E. (2002): Effects of smoking abstinence on visuo-spatial working memory function in schizophrenic patients. *Neuropsychopharmacology*. 26(1): 75-85.
76. Goldberg, T.E. and Gold, J. M. (1995): Neurocognitive deficits in schizophrenia. In, Hirsch, S. R. and Weinberger, D. R. (eds.), *Schizophrenia*. Blackwell: London. Pp. 146-162.
77. Goldman-Rakic, P. S. (1991): Prefrontal cortical dysfunction in schizophrenia: Relevance of working memory. In, Carroll, B. J. & Barret, J. E. (eds.), *Psychopathology and the brain*. Raven: New York. Pp. 1-23.
78. Gray, J. A. and Roth, B. L. (2001): Paradoxical trafficking and regulation of 5-HT_{2A} receptors by agonists and antagonists. *Brain Res. Bull.*, 56(5): 441-51.
79. Hemedah, M.; Coupar, I. M. and Mitchelson, F. J. (1999): [³H] Mesulergine labels 5-HT₇ sites in rat brain and guinea pig ileum but not rat jejunum. *Br. J. Pharmacol.*, 126: 179-188.
80. Hill, B. A. (1971): Principles of medical statistics. 9th ed., London: Limited publication, pp. 147-283.
81. Hill, R. C.; McIvor, R. J.; Wojnar-Horton, R. E.; Hack, H. L. P. and He, H. K. F. (2000): Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. *J. Clin. Psychopharmacol.*, 20(2): 285-6.

82. *Himstreet, J.E. and Daya, M. (1998):*
Hypotension and orthostasis following a risperidone overdose. *Ann. Pharmacother.*, 32(2): 262.
83. *Horing, M. and Lipkin, W. I. (2001):*
Infections and immune factors in the pathogenesis of neurodevelopmental disorders: epidemiology, hypotheses, and animal models. *Ment. Retard. Dev. Disabil. Res. Rev.*, 7(3):200-10.
84. *Hoyer, D. and Martin, G. R. (1996):*
Classification and nomenclature of 5-HT receptors: a comment on current issues. *Behav. Brain Res.*, 73: 263-268.
85. *Ichikawa, J. and Meltzer, H. Y. (1999):*
Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of atypical antipsychotic drugs. *Eur. Arch. Psychiatry Clin. Neurosci.*, 249(4): 90-98.
86. *Iwamoto, K.; Chein, C. and Kato, L. (1987):*
Effects of urethane anesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. *J. Pharmacobiodyn.* 10(6): 280.
87. *Jaffe, J. H. (1990):*
Drug Addiction and Drug Abuse. In, A. Goodman and S. Gilman (Eds.), *Pharmacological Basis of Therapeutics*, Pergmon Press, Elmsford, New York, 1990, pp. 522-573.
88. *Jansen, K. (1990):*
Ketamine, can chronic use impair memory. *Int. J. Addict.*, 25: 133-139.
89. *Janssen, P. A. (1997):*
Atypical antipsychotic drugs. In, *Psychopharmacological Agents*. (Gordon, M., ed.) Academic Press, New York, pp. 128-158.
90. *Janssen, P. A. and Van Bever, W. F. (1978):*
Preclinical psychopharmacology of neuroleptics. In, *Principles of Psychopharmacology*. New York, pp. 279-295.

91. *Javitt, D. C. and Zukin, S. R. (1991):*
Recent advances in phencyclidine model of schizophrenia.
Am. J. Psychiatry, 148: 1301-1308.
92. *Jibson, M. D. and Tandon, R. (1998):*
New atypical antipsychotic medications. *J. Psychiatr. Res.*,
32: 215.
93. *John, C.; Akiko Okamoto, S. C. D. and Martin, B. (2000):*
Risperidone versus haloperidol for prevention of relapses of
schizophrenia and schizoaffective disorders: A long-term
blind comparison. *Eur. Washington University School of
Medicine, St. Louis, Missouri.*
94. *John, H.K.; Laurence, P. K.; John, P. S.; Glenna, K. F.; Richard,
D. and J. Douglas, B. (1996):*
Subanesthetic effects of non-competitive NMDA antagonist,
ketamine, in humans. *Arch. Ges. Psychiatry*, 51: 199-213.
95. *Jones, L. B. (2001):*
Recent cytoarchitectonic changes in the prefrontal cortex of
schizophrenics. *Front. Biosci.*, 6: E148-53.
96. *Kao, L. W.; Kirk, M. A.; Evers, S. J. and Rosenfeld, S. H. (2003):*
Droperidol, QT prolongation, and sudden death: what is the
evidence? *Ann. Emerg. Med.*, 41(4): 546-58.
97. *Karlsson, H.; Bachmann, S.; Schroder, J.; Mc Arthur, J.; Torry, E.
F. and Yolken, R. H. (2001):*
Retroviral RNA identified in the CSF and brains of
individuals with schizophrenia. *Proct. Nalt. Acad. Sci. USA*,
98(8): 4634-9.
98. *Keck, P. and Licht, R. (2000):*
Antipsychotic medications in the treatment of mood
disorders. In, *Schizophrenia and Mood Disorders: The New
Drug Therapies in Clinical Practice* (Buckly, P. F. and
Waddington, J. L., eds.), pp.199-211.
99. *Kiefer, M.; Apel, A. and Weisbrod, M. (2002):*
Arithmetic fact retrieval and working memory in
schizophrenia. *Schizophr. Res.*, 53(3): 219-27.

100. *Kinon, B. J.; Gilmore, J. A.; Liu, H. and Halbreich, U. M. (2003):*
Prevalence of hypoprolactinemia in schizophrenic patients
treated with antipsychotic medications or risperidone (1).
Psychoneuroendocrinology, 28(2): 55-68.
101. *Klimek, V.; Rajkwaszka, G.; Luker, S. N.; Dilly, G.; Meltzer, H.
Y.; Overhol, J. C.; Stockmeyer, C. A. and Ordway, G. A. (1999):*
Brain noradrenergic receptors in major depression and
schizophrenia. *Neuropsychopharmacology*, 21(1): 69-81.
102. *Koo, J. Y. and Ng, T. C. (2002):*
Psychotropic and neuroleptic agents in dermatology:
unapproved use, dosages, or indications. *Clin. Dermatol.*,
20(5): 582-94.
103. *Kratzsch, C.; Peters, F. T.; Kraemer, T. and Weber, A. A. (2003):*
Screening, Library-assisted identification and validated
quantification of fifteen neuroleptics and three of their
metabolites in plasma by liquid chromatography / mass
spectrometry with atmospheric pressure chemical ionization.
J. Mass Spectrom., 38(3): 283-95.
104. *Kroeze, W. K.; Hufeisen, S. J.; Popada, B. A.; Renock, S. M.;
Stienberg, S.; Ernsberg, P.; Jayathilake, K. and Meltzer, H. Y. (2003):*
H1- histamine receptor affinity predicts short-term weight
gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology, 28(3): 519-26.
105. *Kruse, D.; Pantelis, c.; Rudd, R.; Quek, J.; Herbert, P. and
McKinley, M. (2001):*
Treatment of psychogenic polydipsia: comparison of
risperidone and olanzapine, and the effects of an adjuvant
angiotensin II receptor blocking drug (irbesartan). *Aust. N.
Z. J. Psychiatry*, 35(1): 65-8.
106. *Krystal, J. H.; Karper, L.P.; Seibyl, J.P.; Freeman, G. K.; Delaney,
R.; Bremner, J. D. and Heninger, G. R. (1994):*
Subanesthetic effects of non-competitive NMDA
antagonists, ketamine in humans, psychotomimetic,
perceptual, cognitive, and neuroendocrine responses. *Arch.
Gen. Psychiatry*, 51: 199-214.

107. **Kumra, S.; Shaw, M.; Merka, P.; Nakayama, E. and Augustin, R. (2001):**
Childhood-onset schizophrenia: research update. *Can. J. Psychiatry*, 46(10): 923-30.
108. **Kutcher, S. P. (1997):**
Child & Adolescent Psychopharmacology. pp. 431-454. Saunders, Philadelphia.
109. **Laborit, H.; Huguenard, P. and Alluaume, R. (1952):**
Un nouveau stabilisateur végétatif (LE 4560 RP). *Presse Méd.*, 60:206-208.
110. **Lahti, A. C.; Koffle, B.; La Porte, D. and Tamminga, C. A. (1995):**
Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. *Neuropsychopharmacology*, 13: 9-19.
111. **Lahti, A. C.; Weiler, M.; Carlsson, A. and Tamminga, C. A. (1998):**
Effects of the D3 and autoreceptor-preffering dopamine antagonist (+)-UH232 in schizophrenia. *J. Neural Trans.*, 105:719-734.
112. **Langendorff (1895):**
Pflugers Arch. Ges. Physiol., 190, 280. Quoted from pharmacological experiments on Isolated Preparations, 1970 by the staff of Department of Pharmacology, University of Edinburgh. ESS. Livingstone, Edinburgh & Lond.
113. **Lavenstein, B. L. (2003):**
Treatment approaches for children with Tourette's syndrome. *Curr. Neurol. Rep.*, 3(2): 143-8.
114. **Lee, M. A. and Meltzer, H. Y. (2001):**
5-HT 1A receptor dysfunction in female patients with schizophrenia. *Biol. Psychiatry*, 50(10): 785-66.

115. Leonard, S.; Breese, C.; Admas, C.; Benhammou, K.; Gault, J.; Stevens, K.; Lee, M.; Adler, L.; Olincy, S.; Ross, S. and Freedman, R. (2000):

Smoking and schizophrenia: abnormal nicotinic receptor expression. *Eur. J. Pharmacol.*, 393(1-3): 237-42.

116. Leong, G.B. and Silva, J. A. (2003):

Neuroleptic-induced akathisia and violence: a review. *Forensic Sci.*, 48(1): 187-9.

117. Leszczynska-Rodziewicz, A.; Czerski, P. M.; Kapelski, P.; Godlewski, S.; Dmitrzak-Weglarczyk, M.; Rrbakowski, J. and Hauser, J. (2002):

A polymorphism of the norepinephrine transporter gene in bipolar disorder and schizophrenia. *Neuropsychobiology*, 45(4): 182-5.

118. Leweke, F. M.; Giuffrida, A.; Wurster, U.; Emrich, H. M. and Piomelli, D. (1999):

Elevated endogenous cannabinoids in schizophrenia. *Neuroreport*, 10(8): 1665-9.

119. Lewis, D. A. (1997):

Dopamine systems in primate brain. In, *Handbook of Chemical Neuroanatomy*. Vol. 13 (Bloom, F. E.; Björklund, A.; Hökfelt, T. eds.) Elsevier, Amsterdam, pp.263-375.

120. Linner, L.; Wiker, C.; Wadenberg, M. L.; Schalling, M. and Svensson, T. H. (2002):

Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockade-induced dopamine release in the medial prefrontal cortex of the rat. *Neuropsychopharmacology*, 27(5): 691-8.

121. Liu, C. Y.; Chiu, N. Y.; Wu, C. K.; Yaun, L. M.; Hsiao, M. C. and Liao, O. (2003):

Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockade-induced dopamine release in the medial prefrontal cortex of the rat. *Neuropsychopharmacology*, 27(5): 691-8.

122. *Love, R. C. and Nelson, M. W. (2000):*
Pharmacology and clinical experience with risperidone.
Exper. Opin. Pharmacol., 1(7): 1441-53.
123. *Macdonald, R. L. and Olsen, R. W. (1994):*
GABAA receptor channels. *Annu. Rev. Neurosci.*, 17:569-602.
124. *Magnus, (1904):*
Pflügers Arch. Ges. Physiol. 102, 123. Quoted from pharmacological experiments on Isolated Preparations, 1970 by the staff of Department of Pharmacology, University of Edinburgh. ESS. Livingstone, Edinburgh & Lond.
125. *Malaspina, D. (2001):*
Paternal factors and schizophrenia risk: de novo mutations and imprinting. *Schizophr. Bull.*, 27 (3): 379-93.
126. *Malaspina, D.; Halaps, S. and Fennig, S. (2001):*
Advancing paternal age and the risk of schizophrenia. *Arch. Gen. Psychiatry*, 58(4): 361-367.
127. *Malhorta, A. K.; Pinals, D. A.; Weingartner, H.; Sirocco, K.; Missare, C. D. and Pickar, D. (1996):*
NMDA receptor function and human cognition-The effects of ketamine in healthy volunteers.
Neuropsychopharmacology, 14: 301-307.
128. *Malhorta, A. K.; Adler, C. M.; Kennison, S. D.; Elman, I.; Pickar, D. and Breier, A. (1997):*
Clozapine blocks N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. *Biol. Psychiatr.*, 42: 664-668.
129. *Marder, S. R. (1998):*
Antipsychotic medications. In, *The American Psychiatric Press Textbook of Psychopharmacology*. (Schatzberg, A. F. and Nemeroff, C.B., eds.), pp. 309-321.

130. *Marder, S. R. and Meibach, R. (1994):*
Risperidone in the treatment of schizophrenia. *Am. J. Psychiatry*, 151: 825-835.
131. *Marsha, A. W.; Stephen, V. F.; Jessica, Su.; Paul, V. E. and Ming, T.T. (2002):*
Genome scan of 3 quantitative traits in schizophrenia. *Biol. Psychiatry*, 16(4): 123-125.
132. *Masand, P. S. (2000):*
Side effects of antipsychotics in elderly. *J. Clin. Psychiatry*, 55: 33-39.
133. *McLean, P. and Couper, I. M. (1996):*
Characterization of postjunctional 5-HT₇-like and prejunctional 5-HT₃ receptors mediating contraction of rat isolated jejunum. *Eur. J. Pharmacol.*, 312: 215-225.
134. *Meltzer, H. Y. (1999):*
Treatment of schizophrenia and spectrum disorders: pharmacology, psychological treatments, and neurotransmitter interactions. *Biol. Psychiatry*, 46: 1321.
135. *Metzger, E. and Friedman, R. (1993):*
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in medically ill. *J. Clin. Pharmacol.*, 13: 128-32.
136. *Miller, D. D. (2003):*
Clozapine and tardive dyskinesia. *Am. J. Psychiatry*, 160(3): 588.
137. *Miller, D. D.; Andreasen, n. c. ; O'Leary, D. S.; Watkins, G. L.; Boles Ponto, L. L. and Hichw, R. D. (2001):*
Coparison of the side effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. *Biol. Psychiatry*, 49(8): 704-15.
138. *Miller, P.; Byrne, M.; Hodges, A.; Lawrie, S. M.; Owens, D. G. C. and Johnstone, E. V. (2002):*
Schizotypal components in people at high risk of developing schizophrenia: early findings from the Edinburgh High-Risk Study. *Br. J. Psychiatry.*, 180: 179-84.

139. Milou, D. D.; Wen, X. W.; Xio, A.; Ke, L.; Raymond, L. and David, A. (1998):

Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. *J. Clin. Psychopharmacol.*, 18 (6): 477-481.

140. Mjelle, N. and Kringlen, E. (2001):

Schizophrenia: a review, with emphasis on the neurodevelopmental hypothesis. *Nord. J. Psychiatry*, 55(5): 301-9.

141. Moller, H. J. (2000):

Definition, psychopharmacological basis, and clinical evaluation of novel atypical neuroleptics: methodological issues and clinical consequences. *World J. Biol. Psychiatry*, 1(2): 75-91.

142. Morris, B. J. (2003):

Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine differential modulation by antipsychotic drugs. *Neuropsychopharmacology*, 28(2):265-75.

143. Mukaetova-Ladinska, E. B.; Hurt, J.; Horner, W. G.; Harrington, C. R. and Wischik, C. M. (2002):

Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. *Neurosci. Lett.*, 317 (3): 161-5.

144. Mula, M. and Monaco, F. (2002):

Anti-epileptic-antipsychotic drug interactions: a critical review of the evidence. *Clin. Neuropharmacol.*, 25(5): 280-9.

145. Muller, D.; Jol, M. and Lynch, G. (1998):

Contributions of quisqualate and NMDA receptors in the induction and expression of LTP. *Science*, 242: 1694-1697.

146. Murad, I.; Kremer, I.; Dobrusin, M.; Muhaheed, M.; Bannoura, I.; Muller, D. J.; Schulze, T. G.; Resher, A.; Blanaru, M.; Gathas, S.; Tsenter, V.; Rietschel, M.; Belmaker, R. H.; Maier, W. and Ebstein, R. P. (2001):

A family-based study of the Cys23ser 5-HT_{2C} serotonin receptor polymorphism in schizophrenia. *Am. J. Med. Genet.* 105(3):236-8.

147. Murphy, D. L.; Wichems, C.; Li, Q. and Heils, A. (1999):

Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. *Trends Pharmacol. Sci.*, 20:246-252.

148. Neal, C. R. Jr.; Mansour, A.; Reinscheid, R.; Nothaker, H. P.; Civelli, O.; Akil, H. and Watson, S. J. Jr. (1999b):

Opioid receptor-like (ORL 1) receptor distribution in the rat central nervous system: comparison of ORL 1 receptor Mrna expression with ¹²⁵I- (14Tyr)-orphanin FQ binding. *J. Comp. Neurol.*, 412:563-605.

149. Neumeyer, J. L., and Booth, R. G. (2001):

Neuroleptics and anxiolytic agents. In, *Principles of Medicinal Chemistry*, 4th ed. (Foye, W. O.; Williams, D. A. and Lemke, T. L., eds.) Williams & Wilkins, Baltimore.

150. Neve, K. A. and Neve, R. L. eds. (1997):

The Dopamine Receptors. Humana Press, Totowa, NJ.

151. Ohmori, O.; Shinkai, T.; Hori, H.; Kojima, H. and Nakamura, J. (2001):

Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia. *Schizophr. Res.*, 52(1-2): 137-8.

152. Ovalle, S.; Zamanillo, D.; Andreu, F.; Farre, A. J. and Guitart, X. (2001):

Fibroblast growth factor-2 is selectively modulated in the brain by E-5842, a preferential sigma-1 receptor ligand a putative atypical antipsychotic. *Eur. J. Neurosci.*, 13(5): 909-15.

153. *Owens, D. G. C. (1996):*
Adverse effects of antipsychotic drugs. *Drugs*, 51; 893-930.
154. *Paget, G. T. and Barnet, I. M. (1964):*
In evaluation of drug activates pharmacometries Eds.
Laurence, D. R. and Bacharach, A. L.; 1-135. Academic
press London and New York.
155. *Parsian, A. and Cloninger, C. R. (2001):*
Serotonergic pathway genes and subtypes of alcoholism:
association studies. *Pschiatr. Genet.*, 11(2): 89-94.
156. *Patton, S. W.; Misri, S.; Corral, M. R.; Perry, K. F. and Kuan, A. J. (2002):*
Antipsychotic medication during pregnancy and lactation in
women with schizophrenia: evaluating the risk. *Can. J.
Psychiatry*, 47(10): 959-65.
157. *Peckys, D. and Hurd, Y. L. (2001):*
Prodynorphin and kappa opioid receptor mRNA expression
in the cingulated and prefrontal cortices diagnosed with
schizophrenia. *Brain Res. Bull.*, 55(5): 619-24.
158. *Peuskens, J. (1995):*
Risperidone in the treatment of patients with chronic
schizophrenia: a multi-national, multicentre, double-blind,
parallel-group study versus haloperidol. *Br. J. Psychiatry*,
166: 721-726.
159. *Pike, V. W.; Halldin, C. and Wikstrom, H. V. (2001):*
Radioligands for the study of brain 5-HT_{1A} receptors in
vivo. *Prog. Med. Chem.*, 38: 189-247.
160. *Potkin, S. G.; Alva, G.; Fleming, K.; Anand, R.; Keator, D.;
Carreon, D.; Doo, M.; Jin, Y.; Wu, J. C. and Fallon, J. M. (2002):*
A PET study of the pathophysiology of negative symptoms
in schizophrenia. *Am. J. Psychiatry*, 159(2): 227-37.

161. *Prior, T. I. and Baker, G. B. (2003):*
Interactions between the cytochrome P450 system and the second-generation antipsychotics. *J. Psychiatry Neurosci.*, 28(2): 99-112.
162. *Purohit, A.; Herrick-Davis, K. and Teitler, M. (2003):*
Creation, expression, and characterization of a constitutive active mutant of the human serotonin 5-HT₆ receptor. *Synapse*, 47(3): 218-24.
163. *Rabinowitz, I.; Frankenberg, F. R.; Centorrino, F. and Kando, J. (1996):*
The effect of clozapine on saliva flow rate: a pilot study. *Biol. Psychiatry*, 40:1132-1134.
164. *Ratnayake, T. and Liberetto, S. E. (2002):*
No complications with risperidone treatment before and throughout pregnancy and during the nursing period. *J. Clin. Psychiatry*, 63(1): 76-7.
165. *Ravasia, S. (2001):*
Risperidone-induced edema. *Can. J. Psychiatry*, 46(5): 453-4.
166. *Richelson, E. (1999):*
Receptor pharmacology of neuroleptics: relation to clinical effects. *J. Clin. Psychiatry*, 60(10):5-14.
167. *Rosengarten, H. and Quartermain, D. (2002):*
Effect of prenatal administration of haloperidol, risperidone, quetiapine, and olanzapine on spatial learning and retention in adult rats. *Pharmacol. Biochem. Behav.*, 72(3): 575-9.
168. *Roth, B. L.; Cragio, S.C.; Choudhary, M. S.; Uluner, A.; Monsama, F. J.; Shen, Y.; Meltzer, H. Y. and Silbey, D. R. (1994):*
Binding of typical and atypical antipsychotic agents to 5-HT₅ and 5-HT₇ receptors. *J. Pharmacol. Exp. Ther.*, 268: 1403-1410.
169. *Sadock, B. J. and Sadock, V. A. eds. (2000):*
Kaplan and Sadock's Comprehensive Text Book of Psychiatry, 7th ed.

170. Samele, C.; Van-Os, J.; McKenzie, K.; Wright, A.; Gilvarry, C.; Manley, C.; Tattan, T.; Murry, R. (2001):
Does socioeconomic status predict course and outcome in patients with psychosis. Soc. Psychiatry. Psychiatr. Epidemiol., 36(12): 573-81.
171. Sams-Dodd, F. (1998):
A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology, 18: 293-304.
172. Schneider, U.; Leweke, F. M.; Mueller-Vahl, K. R. and Emrich, H. M. (1998):
Cannabinoid/ anandamide system and schizophrenia: is there evidence of association. Pharmacopsychiatry, 31(2): 110-3.
173. Schwartz, J. C.; Arrange, J. M.; Garbarg, M. and Traiffort, E. (1995):
Histamine. In, Psychopharmacology: The Fourth Generation of Progress. (Bloom, F. E. and Kupfer, D. J., eds.) Raven Press, New York, pp.397-406.
174. Schwartz, J. C.; Diaz, J.; Bordet, R.; Griffon, N.; Perachon, S.; Pilon, C.; Ridary, S. and Sokoloff, P. (1998):
Functional implications of multiple dopamine receptor subtypes: the D1/D2 receptor coexistence. Brain Res. Rev., 26: 236-242.
175. Scott, L.; Kruse, M. S.; Forssberg, H.; Brismar, H.; Greengard, P. and Aperia, A. (2002):
Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc. Natl. Acad. Sci. USA, 99(3): 1661-4.
176. Shapiro, M. L. and Caramano, Z. (1990):
NMDA antagonist MK-801 impairs acquisition but not performance of spatial working memory. Psychopharmacology, 18: 231-243.

177. *Sharma, T. and Antonova, L. (2003):*
Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. *Psychiatr. Clin. North Am.*, 26(1): 25-40.
178. *Siegel, A. J.; Baldessarini, R. J.; Kelpser, M. B. and McDonald, J. C. (1998):*
Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. *Harv. Rev. Psychiatry*, 6:190-200.
179. *Silver, H. (2001):*
Fluvoxamine as an adjuvant agent in schizophrenia. *CNS. Drug. Rev.*, 7(3): 283-304.
180. *Singareddy, R. K. and Balon, R. (2001):*
Sleep and suicide in psychiatric patients. *Ann. Clin. Psychiatry*. 13(2): 93-101.
181. *Soares, K. V. and McGarth, J. J. (1999):*
The treatment of tardive dyskinesia: a systemic review and metanalysis. *Schizophr. Res.*, 39:1-16.
182. *Soderstrom, H.; Blennow, K.; Manhem, A. and Forsman, A. (2001):*
CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. *J. Neural. Transm.*, 108(7): 869-78.
183. *Song, F. (1997):*
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. *J. Psychopharmacol.*, 11: 65-71.
184. *Spina, E.; Avenosa, A.; Scordo, M. G.; Ancione, M.; Madia, A.; Gatti, G. and Perucca, E. (2002):*
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. *J. Clin. Psychopharmacol.*, 22(4): 419-23.

185. *Stockmeier, C. A.; Di Carlo, J. J.; Zhang, Y.; Thmpson, P. and Meltzer, H. Y. (1993):*
 Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin 2 and dopamine receptors. *J. Pharmacol. Exp. Ther.*, 266: 1374-84.

186. *Swazey, J. P. (1974):*
 Chlorpromazine in Psychiatry- A Study in Therapeutic innovation. M. I. T. Press, Cambridge, MA.

187. *Taiminen, T.; Ranta, K.; Karlsson, H.; Lauerma, H.; Leinonen, K. M.; Wallenius, E.; Kaljonen, A. and Salokangas, R. K. (2001):*
 Comparison of clinical and best-estimate research DSM-IV diagnosis in a Finnish sample of first-admission psychosis and severe affective disorder. *Nord. J. Psychiatry*, 55(2): 107-11.

188. *Takase, K.; Ohtsuki, T.; Migita, O.; Toru, M.; Inada, T.; Yamakawa-Kobayashi, K. and Arinami, T. (2001):*
 Association of ZNF74 gene genotypes with age-at-onset of schizophrenia. *Schizophr. Res.*, 52 (3): 161-5.

189. *Tan, A. C.; Chong, S. A.; Mahendran, R.; Dong, F. and Tan, C. H. (2001):*
 Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. *Biol. Psychiatry*, 50(2): 144-7.

190. *Tarazi, F. I. and Baldessarini, R. J. (1999):*
 Dopamine D4 receptors: significance for molecular psychiatry at the millennium. *Int. J. Neuropsychopharmacol.*, 2 :41-58.

191. *Tarazi, F. I.; Zhang, K. and Baldessarini, R. J. (2002):*
 Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A, 2C receptors in rat forebrain regions. *Psychopharmacology (Berl)*, 161(3): 263-70.

192. *Tarsy, D.; Tarazi, F. I. and Baldessarini, R. J. (2001):*
 Extrapyramidal dysfunction associated with modern antipsychotic drugs. *CNS Drugs*, in press.

193. *Tauscher, J.; Kuffrle, B.; Asenbaum, S. D.; Tauscher-Wisniewski, S. and Kasper, S. (2002):*
Striatal dopamine-2 receptor occupancy as measured with [123I] iodobenzamide and PECT predict the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. *Psychopharmacology (Berl)*, 162(1): 42-9.
194. *Trenton, A.; Currler, G. and Zwemer, F. (2003):*
Fatalities associated with therapeutic use and overdose of atypical antipsychotics. *CNS Drugs*, 17(5): 307-24.
195. *Tsuang, D.W.; Skol, A. D.; Faraone, S. V.; Bingham, S.; Young, K. A.; Prabhudesai, S.; Haverstock, C. J.; Boehnke, M.; Schellenberg, G. D. and Tsuang, M. T. (2001):*
Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study sample. *Am. J. Med. Genet.* 2001 Dec 8; 105 (8):662-8.
196. *Ullian, M. E.; Islan, M. M.; Robinson, C. J.; Fitzgibbon, W. R.; Tobin, E. T. and Pavul, R. V. (1997):*
Resistance to mineralocorticoids in wistar furth rats. *Am. J. Physiol.*, 272: H 1454-H 1460.
197. *Ulrike, S.; Helmut, S.; Herbert, S. and Bernarhard, A. S. (2000):*
Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. *Br. J. Pharmacol.*, 130: 33-40.
198. *Van den Buuse, M. (2003):*
Acute effects of antipsychotic drugs on cardiovascular responses to stress. *Eur. J. Pharmacol.*, 464(1): 55-62.
199. *Vaswani, M. and Kapur, S. (2001):*
Genetic basis of schizophrenia: trinucleotide repeats. An update. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 25 (6):1187-201.
200. *Viejo, L. F.; Morales, V.; Punal, P.; Perez, J. L. and Sancho, R. A. (2003):*
Risk factors in neuroleptic malignant syndrome. A case-control study. *Acta. Psychiatr. Scand.*, 107(1): 45-9.

201. *Waddington, J. and Casey, D. (2000):*
Comparative pharmacology of classical and novel (second-generation) antipsychotics. In, Schizophrenia and Mood Disorders: The New Drug Therapies In Clinical Practice. (Buckley, P. F. and Waddington, J. L. eds.) Butterworth-Heinemann, Boston, pp.1-13.
202. *Wang, R. Y. and Liang, X. (1998):*
M 100907 and clozapine, but not haloperidol or raclopride prevent neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology, 19: 74-58.
203. *Warnock, J. K. and Morris, D. W. (2002):*
Adverse cutaneous reactions of antipsychotic drugs. Am. J. Clin. Dermatol., 3(9): 629-36.
204. *Wexler, B. E.; Donegan, N.; Stevens, A. A.; Jacob, S. A. (2002):*
Deficits in language-mediated mental operations in patients with schizophrenia. Schizophr. Res., 53(3): 171-9.
205. *Willins, D. L.; Berry, S. A.; Alsayegh, L.; Backstorm, J. R.; Sanders-Bush, E.; Friedman, L. and Roth, B. L. (1999):*
Deficits in language-mediated mental operations in patients with schizophrenia. Schizophr. Res., 53(3): 171-9.
206. *Wirhing, D. A.; Pierre, J. M.; Erhart, S. M. and Boyd, J. A. (2003):*
Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr. Clin. North Am., 26(1): 165-90.
207. *Worrel, J. A.; Marken, P. A.; Beckman, S. E. and Ruehter, V. L. (2000):*
The atypical antipsychotic agents: a critical review. Am. J. Health Sys. Pharm., 57:238-255.
208. *Yamada, Y.; Ohno, Y.; Nakashima, Y.; Fukuda, M.; Takayanagi, R.; Sato, H.; Tsuchia, F.; Sawada, Y. and Iga, T. (2002):*
Prediction and assessment of EPS induced by risperidone based on dopamine D2 receptor occupancy. Synapse, 46(1): 32-7.

209. *Yasui-Furukori, N.; Kondo, T.; Mihara, K.; Suzuki, a.; Inoue, Y.; De Vries, R. and Kaneko, S. (2002):*

Lack of correlation between the steady state concentrations of haloperidol and risperidone. *J. Clin. Pharmacol.*, 42(10): 1083-8.

210. *Zadina, J. E.; Hackler, L.; Ge, L. J. and Kastin, A. J. (1997):*

A potent and selective endogenous agonist for the mu-opiate receptor. *Natre*, 386: 499-502.

211. *Zhao, Q.; Xie, C.; Pesco-Koplowitz, I.; Jia, X. and Parier, J. L. (2003):*

Pharmacokinetic and safety assessments of current administration of risperidone and donepezil. *J. Clin. Pharmacol.*, 43(2): 180-6.